Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer
NCT ID: NCT00199680
Last Updated: 2006-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
42 participants
INTERVENTIONAL
2003-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Early stage cervical cancers at their very beginning, with no lymph node involvement, will be treated either by surgery only or by radiotherapy only, or by both at the same time. At advanced stages, from proximal IB to IIB with bad prognosis (tumour larger than 4 cm and pelvic lymph node involvement), as well as for cancers up to distal stages IIB, III and IVA, treatment relies on radio-chemotherapy, either alone or pre-surgery.
The pre-therapeutic complete examination of the cervical cancer includes a clinical examination and a pelvic MRI in order to look for pelvic and para-aortic lymph nodes and to precise the volume and the spreading of the tumour in the pelvic area.
A meta-analysis estimating the interest of the MRI showed a variable sensitivity and a specificity for the detection of such lymph node metastasis with a sensitivity varying from 24 to 75 % and a specificity between 84 and 100 % according to the studies.
As for the use of an 18-FDG PET scan to detect lymph node involvement, the studies realized so far are performed, usually, on a small number of subjects and with heterogeneous populations. However, it seems that such an examination enables a better detection of lymph nodes than the MRI does, especially for para-aortic lymph nodes depending on the studies, sensitivity varies from 57 to 100 %, and specificity between 92 and 100 %.
We propose a prospective, multicentric and multidisciplinary study for the estimation of diagnosis methods. The main aim is to estimate the interest of the 18-FDG PET scan for the detection of pelvic and para-aortic lymph node metastasis in patients with cervical cancer, in comparison with the MRI. This study should enable to include 380 patients within 3 years. An 18-FDG scintigraphy will be performed before any treatment together with an MRI. A comparison between the sensitivity and the specificity of both examinations will be established and a correlation with the histology of the lymph node dissection will be made.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage I to IV (limited to pelvic) (FIGO Classification) (see appendix 3)
* Age ≥ 18 years old
* No contra-indication to surgery
* Dated, informed and signed consent from the patient
Exclusion Criteria
* Contra-indication to MRI: implantation of an electronic device, metallic or ferromagnetic foreign body
* Serious co-existing affection with vital prognosis
* Diabetes uncontrolled by a classical treatment: glycaemia \> 1.4g/l
* Pregnancy and lactation
* Uncontrolled infection
* Other cancer within the previous 5 years, except skin basal cell carcinoma, or in situ cervical cancer
* Patient with some deficiency preventing her from completely understanding any requirement of the study, which might compromise the patient's consent and/or the observance of the protocol and the consistent participation to the study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Limoges
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique GENET, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Limoges
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gynécologie Obstétrique
Limoges, , France
Médecine Nucléaire
Limoges, , France
Oncologie Médicale
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yves AUBARD, MD
Role: primary
Jacques MONTEIL, MD
Role: primary
Dominique GENET, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Monteil J, Maubon A, Leobon S, Roux S, Marin B, Renaudie J, Genet D, Fermeaux V, Aubard Y, Tubiana-Mathieu N. Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer. Anticancer Res. 2011 Nov;31(11):3865-71.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I03017
Identifier Type: -
Identifier Source: org_study_id